Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue
Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue
复制标题
DOI：
10.1002/mds.10463
复制
发表时间：
2003-08-01
影响因子：
8.6
通讯作者：
Remy, P
中科院分区：
文献类型：
--
作者：
Cochen, V;Ribeiro, MJ;Remy, P
我们比较了6例移植有胎儿中脑细胞的帕金森病患者的[F-18]fluorodopa与[Br-76]-FE-CBT的纹状体摄取，[Br-76]-FE-CBT是多巴胺转运蛋白（DAT）的正电子发射断层扫描（PET）配体，可估计多巴胺神经末梢的密度。在移植的壳核中DAT配体结合没有变化，尽管[F-18]氟多巴摄取显著增加。这一发现表明，移植物诱导的临床获益与宿主纹状体中多巴胺能活性增加的相关性大于多巴胺能神经支配的改善，因此，[F-18]氟多巴仍然是评估移植PD患者的最佳示踪剂。进一步分析表明，移植后的临床和[F-18]氟多巴摄取变化与用于植入的腹侧中脑数量相关。(C)2003年，为社会运动员。
We compared the striatal uptake of [F-18]fluorodopa with [Br-76]-FE-CBT, a positron emission tomography (PET) ligand of the dopamine transporter (DAT), which estimates the density of dopamine nerve terminals, in 6 patients with Parkinson's disease grafted with fetal mesencephalic cells. There was no change in DAT ligand binding in the grafted putamen, despite a significant increase of [F-18]fluorodopa uptake. This finding suggests that the clinical benefit induced by the graft is more related to increased dopaminergic activity than improved dopaminergic innervation in the host striatum and, therefore, that [F-18]fluorodopa remains the optimal tracer to evaluate grafted PD patients. Further analysis showed that the clinical and [F-18]fluorodopa uptake changes after the grafts were correlated with the number of ventral mesencephalae used for implantation. (C) 2003 Movement Disorder Society.